This move is archived. Current quotes and coverage live on the stock page.
Follow BHC
Bausch Health Companies Inc. faced a notable decline in stock value, dropping 3.20% in the last trading session.
Bausch Health Companies Inc. (BHC.TO) experienced a significant downturn in its stock price, closing at CA$6.66 after a 3.20% drop. This decline raises concerns among Canadian investors about the company's short-term performance and market positioning.
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$4.19B
52W high
$12.65
52W low
$6.10
1W change
+20.68%
Beta
0.28
Analyst Price Targets
Based on analyst covering BHC · as of Sep 17, 2026
Wall Street analysts forecast BHC stock price to fall 37.4% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
-37.4% Upside
Current Price
C$11.19
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
85.5%
Annualized
90-Day Vol
77.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$13.38
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$11.88 | C$8.84 – C$15.95 |
| 60 trading days | C$12.60 | C$8.30 – C$19.13 |
| 90 trading days | C$13.38 | C$8.02 – C$22.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be cautious as Bausch Health's recent performance suggests potential underlying issues that may affect future growth and stability.
Bausch Health's stock drops 3.20% in one day.
With a market cap of CA$2.61 billion and a closing price of CA$6.66, Bausch Health's financial metrics raise red flags for investors.
Bull case
Despite the recent decline, Bausch Health is working to expand its product offerings. The recent approval of PrOKEDI® in Quebec could open up long-term growth opportunities for the company.
Bear case
The stock's decline reflects broader concerns about the company's financial health. With a negative profit margin and no P/E ratio, investors may face challenges ahead.
Recent Performance Overview
In the latest trading session, Bausch Health Companies Inc. saw a decline of 3.20%, closing at CA$6.66. This drop is part of a concerning trend for the company, which has struggled with profitability, evidenced by a negative profit margin of -11.47%. Investors are left questioning the company's ability to recover and sustain growth in a competitive market.
Market Reactions and Future Outlook
The market's reaction to Bausch Health's recent performance suggests a lack of confidence among investors. The upcoming announcement of the second quarter 2026 results on July 29, 2026, could provide critical insights into the company's financial health and strategic direction. However, with a market cap of CA$2.61 billion, the pressure is on for Bausch Health to demonstrate a turnaround.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
